About: The development of a GeXP-based multiplex reverse transcription-PCR assay for simultaneous detection of sixteen human respiratory virus types/subtypes

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The development of a GeXP-based multiplex reverse transcription-PCR assay for simultaneous detection of sixteen human respiratory virus types/subtypes Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The development of a GeXP-based multiplex reverse transcription-PCR assay for simultaneous detection of sixteen human respiratory virus types/subtypes
Creator	Li, Jin Ma, Xue-Jun Mao, Nai-Ying Wang, Miao Xu, Wen-Bo Yang, Meng-Jie Zhang, Chen
Source	Medline; PMC
abstract	BACKGROUND: Existing standard non-molecular diagnostic methods such as viral culture and immunofluorescent (DFA) are time-consuming, labor intensive or limited sensitivity. Several multiplex molecular assays are costly. Therefore, there is a need for the development of a rapid and sensitive diagnosis of respiratory viral pathogens. METHODS: A GeXP-based multiplex RT-PCR assay (GeXP assay) was developed to detect simultaneously sixteen different respiratory virus types/subtypes. Seventeen sets of chimeric primers were used to initiate the RT-PCR, and one pair of universal primers was used for the subsequent cycles of the RT-PCR. The specificity of the GeXP assay was examined with positive controls for each virus type/subtype. The sensitivity was evaluated by performing the assay on serial ten-fold dilutions of in vitro-transcribed RNA of all RNA viruses and the plasmids containing the Adv and HBoV target sequence. GeXP assay was further evaluated using 126 clinical specimens and compared with Luminex xTAG RVP Fast assay. RESULTS: The GeXP assay achieved a sensitivity of 20–200 copies for a single virus and 1000 copies when all of the 16 pre-mixed viral targets were present. Analyses of 126 clinical specimens using the GeXP assay demonstrated that GeXP assay and the RVP Fast assay were in complete agreement for 109/126 (88.51%) of the specimens. GeXP assay was more sensitive than the RVP Fast assay for the detection of HRV and PIV3, and slightly less sensitive for the detection of HMPV, Adv, RSVB and HBoV. The whole process of the GeXP assay for the detection of 12 samples was completed within 2.5 hours. CONCLUSIONS: In conclusion, the GeXP assay is a rapid, cost-effective, sensitive, specific and high throughput method for the detection of respiratory virus infections.
has issue date	2012-08-14(xsd:dateTime)
bibo:doi	10.1186/1471-2334-12-189
bibo:pmid	22891685
has license	cc-by
sha1sum (hex)	2857cb1d4c6c446ac30ab4d0cabca0b42d62c465
schema:url	https://doi.org/10.1186/1471-2334-12-189
resource representing a document's title	The development of a GeXP-based multiplex reverse transcription-PCR assay for simultaneous detection of sixteen human respiratory virus types/subtypes
has PubMed Central identifier	PMC3462154
has PubMed identifier	22891685
schema:publication	BMC Infect Dis
resource representing a document's body	covid:2857cb1d4c6c446ac30ab4d0cabca0b42d62c465#body_text
is schema:about of	named entity 'PCR ASSAY' named entity 'assay' named entity 'performing' named entity 'costly' named entity 'demonstrated' named entity 'sequence' named entity 'multiplex' named entity 'infections' named entity 'methods' named entity 'subtype' named entity 'respiratory' named entity 'development' named entity 'subtypes' named entity 'CONTROLS' named entity 'RESPIRATORY VIRUS' named entity 'BASED' named entity 'SUBSEQUENT' named entity '126' named entity 'RVP' named entity 'SIXTEEN' named entity 'MULTIPLEX' named entity 'MOLECULAR' named entity 'FOLD' named entity 'METHOD' named entity 'UNIVERSAL' named entity 'TIME-CONSUMING' named entity 'RNA VIRUSES' named entity 'VIRUS TYPES' named entity 'SIMULTANEOUS' named entity 'SIMULTANEOUSLY' named entity 'LIMITED' named entity 'PRE' named entity 'TO DETECT' named entity 'COMPARED' named entity 'PRESENT' named entity 'IS A' named entity 'CLINICAL' named entity 'VIRUS' named entity 'DIAGNOSIS' named entity 'HIGH THROUGHPUT' named entity 'TRANSCRIBED' named entity 'VIRUS TYPE' named entity 'MIXED' named entity 'LUMINEX' named entity 'PROCESS' named entity 'SPECIMENS' named entity 'PRIMERS' named entity 'EXAMINED' named entity 'IN VITRO' named entity 'COST' named entity 'CONCLUSIONS' named entity 'SEVENTEEN' named entity 'PLASMIDS' named entity 'SENSITIVITY' named entity 'VIRAL' named entity 'FAST' named entity 'USING' named entity 'CONTAINING' named entity 'USED' named entity 'RAPID' named entity 'REVERSE TRANSCRIPTION' named entity 'HUMAN' named entity 'DEVELOPMENT' named entity 'COMPLETED' named entity '2.5' named entity 'EVALUATED' named entity 'COMPLETE AGREEMENT' named entity 'PERFORMING' named entity 'VIRAL CULTURE' named entity 'DEVELOPMENT' named entity 'MULTIPLEX' named entity 'SAMPLES' named entity 'HMPV' named entity 'SERIAL' named entity 'METHODS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software